Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Nasus Pharma Ltd. ( (NSRX) ).
Nasus Pharma Ltd. announced on March 4, 2026, that it will shift its March 5 Special General Meeting of Shareholders to a virtual-only format due to the security situation in Israel and related restrictions on public gatherings. The move underscores how ongoing regional instability is directly affecting the company’s corporate governance processes, forcing shareholders to rely on online participation rather than in‑person engagement for this key decision-making forum.
The company maintained the previously scheduled time of March 5, 2026, at 2:00 p.m. Israel time, but confirmed that no physical attendance will be permitted at any location. This adjustment highlights the operational flexibility required of Israeli-listed firms in the current environment and may influence how both local and international shareholders assess access, transparency, and continuity of governance at Nasus Pharma.
The most recent analyst rating on (NSRX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is an Israel-based pharmaceutical company that reports as a foreign private issuer under U.S. securities regulations. The company’s shares are registered with the U.S. Securities and Exchange Commission and it files its annual reports on Form 20-F, reflecting an orientation toward global capital markets and international investors.
Average Trading Volume: 6,176
Technical Sentiment Signal: Strong Sell
For detailed information about NSRX stock, go to TipRanks’ Stock Analysis page.